Results 41 to 50 of about 5,159 (106)

Enzyme-substrate-inactivator complex formation can impact time-dependent inhibition kinetics. [PDF]

Drug Metab Dispos
Yadav J, Wahlstrom J, Korzekwa K, Nagar S.   +3 more
europepmc   +1 more source

Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates. [PDF]

Clin Pharmacol Drug Dev
D'Cunha R, Qian Y, Hao S, Eccleston J, Levy GF, Gannu S, Rizzo DG, Liu W, Mohamed MF.   +8 more
europepmc   +1 more source

Physiologically-Based Pharmacokinetic Model-Informed Labeling for Cariprazine Drug Interactions With CYP3A Inhibitors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Riad MMH, Marroum P, Shebley M, Xiong H.
europepmc   +1 more source

Assessment of the Intestinal CYP3A Contribution to Drug Interactions with Extended-Release Tacrolimus (LCPT) Using Grapefruit Juice. [PDF]

Clin Pharmacol Drug Dev
Alabi A, Kerr JS, Shah M, Khan A, Ma JD, Suhandynata RT, Momper JD, Tsunoda SM.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. [PDF]

CPT Pharmacometrics Syst Pharmacol
Watanabe A, Gill KL, Chen KF, Jones HM, De Sousa Mendes M, Gardner I, Kotsuma M.   +6 more
europepmc   +1 more source

Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo. [PDF]

Cancer Chemother Pharmacol
Drabison T, Ahmed EA, Colasanti N, Weber RH, Sparreboom A, Eisenmann ED.   +5 more
europepmc   +1 more source

Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants. [PDF]

Clin Transl Sci
Luckey A, Larson KB, Rayad N, Heep M, Delhomme S, Kornmann G, Mueller JP, O'Donnell JP, O'Brien S, Fuhr R, Gillon JY.   +10 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P-gp Modulators. [PDF]

Clin Transl Sci
Watanabe A, Okudaira N, Tachibana M, Kazui M, Kotsuma M, Shimizu T, Lau Y.   +6 more
europepmc   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes. [PDF]

J Clin Pharmacol
Zhou XJ, Vo A, Morelli G, Montrond M, Lynch S, Pietropaolo K, Belanger B, Good S, Horga A, Agrawal N, Hammond J.   +10 more
europepmc   +1 more source

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. [PDF]

Clin Pharmacol Ther
Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, Quinney SK, Desta Z, Skaar TC, Tisdale JE, Shugg T.   +10 more
europepmc   +1 more source